| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6199646 | Ophthalmology | 2015 | 9 Pages |
Abstract
In both VISTA and VIVID, the 52-week visual and anatomic superiority of IAI over laser control was sustained through week 100, with similar efficacy in the 2q4 and 2q8 groups. Safety in these studies was consistent with the known safety profile of IAI.
Keywords
IAILOCFDRSSBCVANEI VFQ-25ETDRS2q8DME2q4CStDiabetic macular edemastandard deviationOctbest-corrected visual acuityintravitreal aflibercept injectionOptical coherence tomographyearly treatment diabetic retinopathy studyadverse eventVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)Diabetic Retinopathy Severity Scale
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
David M. MD, Ursula MD, Diana V. MD, Frank G. MD, David S. MD, Edoardo MD, Jeffrey S. MD, Hiroko MD, Peter K. MD, Dennis M. MD, Quan D. MD, Glenn J. MD, Jason S. MD, Christian MD, Yuhwen PhD, Thomas PhD, George D. MD, PhD, Neil PhD, Jean-François MD,